Abstract
The underlying drivers of scientific processes have been rapidly evolving, but the ever-present need for research funding is typically foremost amongst these. Successful laboratories are embracing this reality by making certain that their projects have commercial value right from the beginning of the project conception. Which factors to be considered for commercial success need to be well thought out and incorporated into a project plan with similar levels of detail as would be the technical elements. Specific examples of commercial outcomes in the field of Immunoproteomics are exemplified in this discussion.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Covey SR (1989) The 7 habits of highly effective people. Simon & Schuster, New York
Kassicieh SK, Radosevich HR (1994) From lab to market: commercialization of public sector technology. Plenum, New York
Sarna L (2000) Guide to commercializing R&D. Jewel Publications Ltd., Montreal, QC
Jolly VK (1997) Commercializing new technologies: getting from mind to market. Harvard Business School Press, Boston, MA
Kaplam RS, Norton DP (2004) Strategy maps: converting intangible assets into tangible outcomes. Harvard Business School Publishing Corporation, Boston, MA
Tidd J, Bessant J, Pavitt K (2001) Managing innovation: integrating technological, market and organizational change. Wiley, Chichester
Lane RP, Daly PB (2006) Managing biotechnology risk from concept to commercialization: a strategic approach. BioExecutive International April 2006
Branca MA (2004) The path to market for genomics-based diagnostics. Spectrum diagnostics and related technologies. Decision Resources, Waltham, MA
Krul KG (1999) Pharmagogenomics: key technologies, major players, and lingering questions. Spectrum pharmaceutical industry dynamics. Decision Resources, Waltham, MA
Miller T (2000) Challenges in genomics-based biotechnology: Part I: building a proprietary technology portfolio. Spectrum pharmaceutical industry dynamics. Decision Resources, Waltham, MA
Miller T (2000) Challenges in genomics-based biotechnology: Part II: key genomics leaders. Spectrum pharmaceutical industry dynamics. Decision Resources, Waltham, MA
Haberman A (2001) Protein biochips: an emerging technology for proteomics. Spectrum drug discovery and design. Decision Resources, Waltham, MA
Lockwood D, Branca M (2001) Genomics dealmaking in 2000 and future outlook, Part II: proteomics and functional genomics. Spectrum drug discovery and design. Decision Resources, Waltham, MA
Krul KG (2001) Advances in proteomics: its use and commercialization. Spectrum pharmaceutical industry dynamics. Decision Resources, Waltham, MA
Matheson A (1998) Profiting from proteomics: strategies and technologies. Scrip Reports, BS 982, UK
Crowther G (2012) Biomarker discovery methods evolving. Genet Eng Biotechnol News 32(9):44
Mou Z, He Y, Wu Y (2009) Immunoproteomics to identify tumor-associated antigens eliciting humoral response. Cancer Lett 278:123–129
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Ferguson, S.M. (2013). Commercial Considerations for Immunoproteomics. In: Fulton, K., Twine, S. (eds) Immunoproteomics. Methods in Molecular Biology, vol 1061. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-589-7_22
Download citation
DOI: https://doi.org/10.1007/978-1-62703-589-7_22
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-588-0
Online ISBN: 978-1-62703-589-7
eBook Packages: Springer Protocols